View filters (6 in use)

Updating results

547 results

Sort: Relevance | Date

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In development [GID-TA10420] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Technology appraisal guidance In development

Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535

In development [GID-TA10412] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Technology appraisal guidance In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Patiromer for treating hyperkalaemia [ID877]

In development [GID-TA10273] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

In development [GID-TA10351] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Mogamulizumab for treated mycosis fungoides or Sézary syndrome T-cell lymphoma ID1405

In development [GID-TA10305] Expected publication date: 16 September 2020

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: TBC

Technology appraisal guidance In development

Solriamfetol for treating excessive sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]

In development [GID-TA10466] Expected publication date: 15 April 2020

Technology appraisal guidance In development

Fremanezumab for preventing migraine [ID1368]

In development [GID-TA10339] Expected publication date: TBC

Technology appraisal guidance In development

Sotagliflozin, in combination with insulin, for treating type 1 diabetes [ID1376]

In development [GID-TA10376] Expected publication date: 08 January 2020

Technology appraisal guidance In development

Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]

In development [GID-TA10444] Expected publication date: 08 January 2020

Technology appraisal guidance In development

Niraparib for maintenance treatment of platinum-sensitive ovarian, fallopian tube and peritoneal cancer after response to 1 course of platinum-based chemotherapy [ID1680]

In development [GID-TA10551] Expected publication date: TBC

Technology appraisal guidance In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Entrectinib for treating NTRK fusion-positive solid tumours ID1512

In development [GID-TA10414] Expected publication date: 12 February 2020

Technology appraisal guidance In development

Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404

In development [GID-TA10327] Expected publication date: TBC

Technology appraisal guidance In development

Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

In development [GID-TA10496] Expected publication date: 21 October 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

In development [GID-TA10222] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma ID1276

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]

In development [GID-TA10415] Expected publication date: TBC

Technology appraisal guidance In development

Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Diagnostics guidance In development

KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Diagnostics guidance In development

Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Diagnostics guidance In development

SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Medical technologies guidance In development

Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Medical technologies guidance In development

Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

In development [GID-MT163] Expected publication date: TBC

Medical technologies guidance In development

SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Medical technologies guidance In development

The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Medical technologies guidance In development

Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Medical technologies guidance In development

OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Medical technologies guidance In development

The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Medical technologies guidance In development

Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

NICE guideline In development

Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

NICE guideline In development

Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

NICE guideline In development

Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

NICE guideline In development